Abstract
Background: To study the roles of micro ribonucleic acid (miR)-155 host gene (MIR155HG) and tumor necrosis factor-α (TNF-α) in the evaluation of prognosis of patients with systemic lupus erythematosus (SLE).
Methods: A total of 130 patients with SLE admitted to our hospital were selected, and the SLE disease activity index (SLEDAI) score was given. The expressions of MIR155HG and TNF-α were detected via quantitative reverse transcription-polymerase chain reaction (qRT-PCR), the incidence of complications during treatment was observed, and the associations of MIR155HG and TNF-α with SLEDAI before treatment and complications were analyzed. All patients were followed up after discharge, and the related factors to the prognosis of patients were analyzed via Cox regression analysis.
Results: The levels of MIR155HG and TNF-α were higher in patients with an SLEDAI score of 10-14 points than those in patients with an SLEDAI score of 5-9 points and 0-4 points. MIR155HG and TNF-α were positively correlated with the incidence of infection, renal damage and cardiac damage. Moreover, there was also a positive correlation between the expressions of serum MIR155HG and TNF-α in SLE patients. SLEDAI score ≥10 points, complications during hospitalization, and highly-expressed MIR155HG and TNF-α were risk factors related to the prognosis of patients.
Conclusion: MIR155HG and TNF-α are key regulators in the pathogenesis of SLE, and they can affect the prognosis of patients. Such a finding provides potential new targets for the treatment of SLE.
Keywords
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.